Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy

Article

Angie Drakulich, Editorial Director of BioPharm International, talks with Mike Clayman, CEO of Flexion Therapeutics. Based in Woburn, MA, the companyworks to develop therapeutics for musculoskeletal disorders. In this podcast, Clayman discusses why the company chose to focus on a full range of treatments for one particular disease, osteoarthritis, and how the approach has helped the company fill its biopharmaceutical pipeline and market space. This is an audio podcast. Posted Apr. 2012.

Angie Drakulich, Editorial Director of BioPharm International, talks with Mike Clayman, CEO of Flexion Therapeutics. Based in Woburn, MA, the company works to develop therapeutics for musculoskeletal disorders. In this podcast, Clayman discusses why the company chose to focus on a full range of treatments for one particular disease, osteoarthritis, and how the approach has helped the company fill its biopharmaceutical pipeline and market space. Posted Apr. 2012.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.